BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33030757)

  • 1. Prediction of pre-eclampsia-related complications in women with suspected or confirmed pre-eclampsia: development and internal validation of clinical prediction model.
    Saleh L; Alblas MM; Nieboer D; Neuman RI; Vergouwe Y; Brussé IA; Duvekot JJ; Steyerberg EW; Versendaal HJ; Danser AHJ; Meiracker AHVD; Verdonk K; Visser W
    Ultrasound Obstet Gynecol; 2021 Nov; 58(5):698-704. PubMed ID: 33030757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble fms-like tyrosine kinase-1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre-eclampsia.
    Saleh L; van den Meiracker AH; Geensen R; Kaya A; Roeters van Lennep JE; Duvekot JJ; Verdonk K; Steegers EAP; Russcher H; Danser AHJ; Visser W
    Ultrasound Obstet Gynecol; 2018 Jun; 51(6):751-757. PubMed ID: 28600845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting.
    Zeisler H; Llurba E; Chantraine FJ; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Schoedl M; Grill S; Hund M; Verlohren S
    Ultrasound Obstet Gynecol; 2019 Mar; 53(3):367-375. PubMed ID: 30014562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal assessment of angiogenic markers in prediction of adverse outcome in women with confirmed pre-eclampsia.
    Binder J; Palmrich P; Kalafat E; Haberl C; Schirwani N; Pateisky P; Khalil A
    Ultrasound Obstet Gynecol; 2023 Dec; 62(6):843-851. PubMed ID: 37265117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stratification of pregnancy care based on risk of pre-eclampsia derived from biophysical and biochemical markers at 19-24 weeks' gestation.
    Litwinska M; Litwinska E; Astudillo A; Syngelaki A; Wright A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2021 Sep; 58(3):360-368. PubMed ID: 33794058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Copeptin and mid-regional pro-atrial natriuretic peptide in women with suspected or confirmed pre-eclampsia: comparison with sFlt-1/PlGF ratio.
    Neuman RI; van der Meer MMA; Saleh L; van den Berg SAA; van den Meiracker AH; Danser AHJ; Visser W
    Ultrasound Obstet Gynecol; 2020 Dec; 56(6):872-878. PubMed ID: 31975510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should angiogenic markers be included in diagnostic criteria of superimposed pre-eclampsia in women with chronic hypertension?
    Binder J; Kalafat E; Palmrich P; Pateisky P; Khalil A
    Ultrasound Obstet Gynecol; 2022 Feb; 59(2):192-201. PubMed ID: 34165863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STATIN trial: predictive performance of competing-risks model in screening for pre-eclampsia at 35-37 weeks' gestation.
    Döbert M; Wright A; Varouxaki AN; Mu AC; Syngelaki A; Rehal A; Delgado JL; Akolekar R; Muscettola G; Janga D; Singh M; Martin-Alonso R; Dütemeyer V; De Alvarado M; Atanasova V; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2022 Jan; 59(1):69-75. PubMed ID: 34580947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. sFlt-1/PlGF for prediction of early-onset pre-eclampsia: STEPS (Study of Early Pre-eclampsia in Spain).
    Perales A; Delgado JL; de la Calle M; García-Hernández JA; Escudero AI; Campillos JM; Sarabia MD; Laíz B; Duque M; Navarro M; Calmarza P; Hund M; Álvarez FV;
    Ultrasound Obstet Gynecol; 2017 Sep; 50(3):373-382. PubMed ID: 27883242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of N-terminal pro-B natriuretic peptide to soluble fms-like tyrosine kinase-1/placental growth factor ratio > 38 improves prediction of pre-eclampsia requiring delivery within 1 week: a longitudinal cohort study.
    Sabriá E; Lequerica-Fernández P; Lafuente-Ganuza P; Eguia-Ángeles E; Escudero AI; Martínez-Morillo E; Barceló C; Álvarez FV
    Ultrasound Obstet Gynecol; 2018 Jun; 51(6):758-767. PubMed ID: 29498431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
    Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maternal cardiac function at 19-23 weeks' gestation in prediction of pre-eclampsia.
    Gibbone E; Wright A; Vallenas Campos R; Sanchez Sierra A; Nicolaides KH; Charakida M
    Ultrasound Obstet Gynecol; 2021 May; 57(5):739-747. PubMed ID: 33294998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of pre-eclampsia within 4 weeks of sFlt-1/PlGF ratio > 38: comparison of performance at 31-34 vs 35-37 weeks' gestation.
    Dragan I; Wright D; Fiolna M; Leipold G; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Feb; 49(2):209-212. PubMed ID: 27671743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contingent screening in stratification of pregnancy care based on risk of pre-eclampsia at 19-24 weeks' gestation.
    Litwinska M; Litwinska E; Bouariu A; Syngelaki A; Wright A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2021 Oct; 58(4):553-560. PubMed ID: 34309913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of pregnancies after combined screening for pre-eclampsia at 19-24 weeks' gestation.
    Litwinska M; Syngelaki A; Wright A; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2018 Sep; 52(3):365-372. PubMed ID: 29943498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maternal serum soluble fms-like tyrosine kinase-1 at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
    Tsiakkas A; Mendez O; Wright A; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Apr; 47(4):478-83. PubMed ID: 26582564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of hypertensive disorders after screening at 36 weeks' gestation: comparison of angiogenic markers with competing-risks model.
    Schiattarella A; Magee LA; Wright A; Syngelaki A; Akolekar R; Von Dadelszen P; Nicolaides KH
    Ultrasound Obstet Gynecol; 2023 Sep; 62(3):345-352. PubMed ID: 37329494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of angiogenic markers in pregnancy with fetal growth restriction.
    Palmrich P; Kalafat E; Pateisky P; Schirwani-Hartl N; Haberl C; Herrmann C; Khalil A; Binder J
    Ultrasound Obstet Gynecol; 2024 May; 63(5):619-626. PubMed ID: 37774098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenic imbalance in pre-eclampsia and fetal growth restriction: enhanced soluble fms-like tyrosine kinase-1 binding or diminished production of placental growth factor?
    Kluivers ACM; Biesbroek A; Visser W; Saleh L; Russcher H; Danser AHJ; Neuman RI
    Ultrasound Obstet Gynecol; 2023 Apr; 61(4):466-473. PubMed ID: 36191149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of three commercially available placental growth factor-based tests in women with suspected preterm pre-eclampsia: the COMPARE study.
    McCarthy FP; Gill C; Seed PT; Bramham K; Chappell LC; Shennan AH
    Ultrasound Obstet Gynecol; 2019 Jan; 53(1):62-67. PubMed ID: 29575304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.